Genetically Engineered Mouse Models of Pancreatic Cancer

Overview

Journal Cancer J

Specialty Oncology

Date 2012 Nov 29

PMID 23187836

Citations 60

Authors

Christoph Benedikt Westphalen

Kenneth P Olive

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma is the 10th most common cancer and the fourth leading cause of cancer-related death in the United States. Despite great effort, the prognosis for patients with this disease remains dismal with a 5-year survival rate of just 4% to 6%. Although several important advances have improved our understanding of the underlying biology of pancreatic cancer, this knowledge has not translated into novel therapeutic approaches and effective systemic or targeted therapies. Pancreatic cancer is one of the malignancies most difficult to treat, with remarkable intrinsic resistance to both standard and targeted chemotherapy as well as ionizing radiation. Surgical intervention remains the only potentially curative approach. However, most patients present with inoperable and/or metastatic disease and are therefore excluded from surgery. Accordingly, new therapeutic options are desperately needed. In vivo models to study innovative and alternative treatment approaches are of major importance. A variety of genetically engineered mouse models of pancreatic cancer have been developed over the last decade. However, these models display different characteristics, and not all of them are suited for preclinical studies. In this review, we aim to review the mouse models available, their experimental use, their clinical relevance and limitations, and future directions.

Citing Articles

Regulation of ROS signaling by TIGAR induces cancer-modulating responses in the tumor microenvironment.

Cheung E, Strathdee D, Stevenson D, Coomes J, Blyth K, Vousden K Proc Natl Acad Sci U S A. 2024; 121(50):e2416076121.

PMID: 39636862 PMC: 11648893. DOI: 10.1073/pnas.2416076121.

A molecular pathway for cancer cachexia-induced muscle atrophy revealed at single-nucleus resolution.

Zhang Y, Dos Santos M, Huang H, Chen K, Iyengar P, Infante R Cell Rep. 2024; 43(8):114587.

PMID: 39116208 PMC: 11472345. DOI: 10.1016/j.celrep.2024.114587.

Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer.

Mustafa M, Abbas K, Alam M, Habib S, Zulfareen , Hasan G Front Oncol. 2024; 14:1427802.

PMID: 39087024 PMC: 11288929. DOI: 10.3389/fonc.2024.1427802.

Current trends and future prospects of drug repositioning in gastrointestinal oncology.

Fatemi N, Karimpour M, Bahrami H, Zali M, Chaleshi V, Riccio A Front Pharmacol. 2024; 14:1329244.

PMID: 38239190 PMC: 10794567. DOI: 10.3389/fphar.2023.1329244.

A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice.

Quilbe A, Mustapha R, Duchene B, Kumar A, Werkmeister E, Leteurtre E Front Immunol. 2023; 14:1267279.

PMID: 38098486 PMC: 10720041. DOI: 10.3389/fimmu.2023.1267279.

References

Quante M, Wang T . Stem cells in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol. 2009; 6(12):724-37. PMC: 2902988. DOI: 10.1038/nrgastro.2009.195. View

Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald R, Wright C . The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet. 2002; 32(1):128-34. DOI: 10.1038/ng959. View

Morton J, Jamieson N, Karim S, Athineos D, Ridgway R, Nixon C . LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology. 2010; 139(2):586-97, 597.e1-6. PMC: 3770904. DOI: 10.1053/j.gastro.2010.04.055. View

Ijichi H, Chytil A, Gorska A, Aakre M, Fujitani Y, Fujitani S . Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev. 2006; 20(22):3147-60. PMC: 1635149. DOI: 10.1101/gad.1475506. View

Pan F, Wright C . Pancreas organogenesis: from bud to plexus to gland. Dev Dyn. 2011; 240(3):530-65. DOI: 10.1002/dvdy.22584. View

Hezel A, Gurumurthy S, Granot Z, Swisa A, Chu G, Bailey G . Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol. 2008; 28(7):2414-25. PMC: 2268441. DOI: 10.1128/MCB.01621-07. View

Seidler B, Schmidt A, Mayr U, Nakhai H, Schmid R, Schneider G . A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc Natl Acad Sci U S A. 2008; 105(29):10137-42. PMC: 2481330. DOI: 10.1073/pnas.0800487105. View

Tian H, Callahan C, DuPree K, Darbonne W, Ahn C, Scales S . Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A. 2009; 106(11):4254-9. PMC: 2647977. DOI: 10.1073/pnas.0813203106. View

Mazur P, Einwachter H, Lee M, Sipos B, Nakhai H, Rad R . Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2010; 107(30):13438-43. PMC: 2922150. DOI: 10.1073/pnas.1002423107. View

10.

Beatty G, Chiorean E, Fishman M, Saboury B, Teitelbaum U, Sun W . CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331(6024):1612-6. PMC: 3406187. DOI: 10.1126/science.1198443. View

11.

Ying H, Elpek K, Vinjamoori A, Zimmerman S, Chu G, Yan H . PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 2011; 1(2):158-69. PMC: 3186945. DOI: 10.1158/2159-8290.CD-11-0031. View

12.

Von Hoff D, Ramanathan R, Borad M, Laheru D, Smith L, Wood T . Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011; 29(34):4548-54. PMC: 3565012. DOI: 10.1200/JCO.2011.36.5742. View

13.

Carriere C, Seeley E, Goetze T, Longnecker D, Korc M . The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A. 2007; 104(11):4437-42. PMC: 1810329. DOI: 10.1073/pnas.0701117104. View

14.

Singh M, Lima A, Molina R, Hamilton P, Clermont A, Devasthali V . Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010; 28(6):585-93. DOI: 10.1038/nbt.1640. View

15.

Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue C . Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003; 3(6):565-76. DOI: 10.1016/s1535-6108(03)00140-5. View

16.

Carriere C, Young A, Gunn J, Longnecker D, Korc M . Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage. PLoS One. 2011; 6(11):e27725. PMC: 3225359. DOI: 10.1371/journal.pone.0027725. View

17.

Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L . Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology. 2011; 140(4):1303-1313.e1-3. PMC: 3066280. DOI: 10.1053/j.gastro.2010.12.039. View

18.

Gibbs J, Sigal I, Poe M, Scolnick E . Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A. 1984; 81(18):5704-8. PMC: 391779. DOI: 10.1073/pnas.81.18.5704. View

19.

Perez-Mancera P, Guerra C, Barbacid M, Tuveson D . What we have learned about pancreatic cancer from mouse models. Gastroenterology. 2012; 142(5):1079-92. DOI: 10.1053/j.gastro.2012.03.002. View

20.

Olive K, Jacobetz M, Davidson C, Gopinathan A, McIntyre D, Honess D . Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933):1457-61. PMC: 2998180. DOI: 10.1126/science.1171362. View